Drug intelligence / Profile preview

efalizumab + acitretin

Development stage: Unknown
Lead developer: Genentech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Subcutaneous, Oral

Overview

A combination therapy consisting of efalizumab (a humanized monoclonal antibody against CD11a) and acitretin (a second-generation monoaromatic retinoid). This specific combination is not well-documented in the literature based on the provided search results. Acitretin is used in the treatment of psoriasis and works by normalizing epidermal cell proliferation and differentiation. Efalizumab was previously used for psoriasis but was withdrawn from the market.

Targets

ITGAL (Integrin alpha L (CD11a))

Beyond the preview

Go deeper on efalizumab + acitretin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on efalizumab + acitretin.

Explore the full profile